IMAC Antibody Complexes for Cancer Killing Without GVHD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell-mediated immunotherapy for cancer, particularly allogeneic stem cell transplantation, is hindered by life-threatening complications such as graft versus host disease (GVHD) and high relapse rates, despite the use of matched or mismatched donor lymphocytes, and commercially available bispecific antibodies are limited in versatility and cost-effectiveness.
Innovation Solution
Development of multifunctional immunotherapeutic monoclonal antibody complexes (IMAC) comprising two different monoclonal antibodies connected via avidin-biotin or other bonds, targeting cancer cells and immune cells, optionally with activating cytokines, to induce long-lasting anti-cancer immunity and minimize GVHD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic stem cell transplantation is used to treat cancer, then anti-cancer effects are improved, but graft versus host disease and infections occur
Solution Approach 1:
The invention segments the therapeutic approach into two distinct components: (1) administration of intentionally mismatched donor lymphocytes for cytotoxic anti-cancer activity, and (2) subsequent induction of host anti-cancer immunity through cancer antigen exposure. This segmentation allows the mismatched lymphocytes to be transiently present for cancer killing without establishing durable engraftment that would cause GVHD, as the lymphocytes are naturally rejected after serving their therapeutic purpose.
Solution Approach 2:
The invention uses cancer antigens (from tumor cells or cancer vaccines) as an intermediary to bridge the mismatched donor lymphocytes and the host immune system. The mismatched lymphocytes kill cancer cells, releasing cancer antigens that then serve as intermediaries to sensitize and activate host T cells, thereby inducing long-lasting host anti-cancer immunity without requiring persistent presence of the donor lymphocytes.
2Object-affected harmful factors
If matched donor lymphocytes are used to prevent GVHD, then relapse rate increases
Solution Approach 1:
The invention inverts the conventional approach by using intentionally mismatched (non-matched) donor lymphocytes instead of matched ones. The mismatch is deliberately exploited to achieve transient lymphocyte circulation for cancer killing, followed by natural rejection that prevents GVHD. The host anti-cancer immunity is then induced through cancer antigen exposure, compensating for the initial mismatch and ensuring anti-relapse protection.
3Ease of manufacture
If commercially available bisspecific antibodies are used for targeting, then versatility is limited
Solution Approach 1:
The invention creates a universal platform using intentionally mismatched donor lymphocytes that can target multiple cancer types through different cancer-associated antigens. The same mismatched lymphocyte population can be used across various cancers (lymphomas, leukemias, solid tumors) by adjusting the cancer vaccine or antigen exposure component, making the approach broadly applicable rather than limited to specific antibody-cancer pairings.
4Reliability
If allogeneic SCT is performed with high-dose chemotherapy, then cancer control improves, but treatment toxicity increases
Solution Approach 1:
The invention extracts and eliminates the high-dose chemotherapy component from the treatment protocol, retaining only the essential element of donor lymphocyte administration. The intentionally mismatched donor lymphocytes alone provide sufficient anti-cancer effects through their cytotoxic activity and induction of host immunity, making the hazardous high-dose chemotherapy conditioning unnecessary and thereby reducing treatment toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IMACs effectively eliminate cancer cells, induce memory T cells, and provide broad-spectrum anti-cancer immunity, reducing GVHD risks and treatment costs, while being readily accessible and adaptable to various cancer types.
Implementation Method 1
Targeting of killer cells against cancer cells can be enhanced by concomitant administration of antibodies against cancer-associated antigens (e.g., CD20 or CD19 against malignant B cells), thus resulting in antibody-dependent cell-mediated cytotoxicity.
Implementation Method 2
when recipient's dendritic cells pulsed with cancer antigens sensitized recipient's T cells, resulting in induction of long-lasting memory T cells that could eliminate a fresh challenge of lethal inoculum of cancer cells
Implementation Method 3
multifunctional immunotherapeutic monoclonal antibody complexes (IMAC) comprising two different monoclonal antibodies connected via avidin-biotin or other bonds
Data Source
AI summary
Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patients antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.